Pacira BioSciences logo

Pacira BioSciences

PCRX | NASDAQ
Chart Builder DCF Calculator
$36.48
+$0.02 (+0.05%)
At close: Nov 16, 2026, 4:00 PM ET
$36.48
+$0.01 (+0.01%)
After-hours: Nov 16, 2026, 7:30 PM ET
+0.05%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 16, 2026
57.4
Fundamentals Strong
Market Sentiment Neutral
Moat Narrow
Sector Rank #152/1021 (Top 15%)

Key Statistics

Market Data

Market Cap $1.46B
1D Range
36.48 36.49
52W Range
19.16 36.49

Valuation (TTM)

PE 39.23
PB 2.04
EV/EBITDA 11.42

Valuation (NTM)

Forward PE 12.57
Forward PEG -20.36
Price Target $32.00
Loading financial charts...

Profile

Operating within the United States, Pacira BioSciences, Inc. is dedicated to providing healthcare professionals and their patients with non-opioid solutions for pain management and regenerative health...

Sector Healthcare
Employees 827
IPO Date Feb 3, 2011
Fiscal Year January - December

Latest News

Ingram Micro Holding Set to Join S&P SmallCap 600

5 days ago · prnewswire.com

Ingram Micro Holding Set to Join S&P SmallCap 600
PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders

17 days ago · businesswire.com

PCRX Stock Alert: Halper Sadeh LLC is Investigating Whether Pacira BioSciences, Inc. is Obtaining a Fair Price for its Shareholders
Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut

3 months ago · zacks.com

Pacira Q2 Earnings & Revenues Beat, 2026 Sales Outlook Cut
Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript

3 months ago · seekingalpha.com

Pacira BioSciences, Inc. (PCRX) Q2 2026 Earnings Call Transcript
Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates

3 months ago · zacks.com

Pacira (PCRX) Tops Q2 Earnings and Revenue Estimates
Pacira BioSciences Reports Second Quarter 2026 Financial Results

3 months ago · globenewswire.com

Pacira BioSciences Reports Second Quarter 2026 Financial Results
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process

4 months ago · globenewswire.com

Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026

4 months ago · globenewswire.com

Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026
PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada

7 months ago · globenewswire.com

PharmaCorp Completes Acquisition of Pharmacy Files in Western Canada
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

7 months ago · zacks.com

Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

Earnings

Latest Earnings
Nov 5, 2026
EPS
$0.72
Miss -4.26%
REV
$176.65M
Miss -2.81%
Next Earnings
Mar 4, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
7
Consensus
Hold
Price Target
$32.00
Downside
-12.28%
Buy (0)
Hold (7)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.